BackKadmon Holdings Overview

Kadmon Holdings EBIT

Latest ebit for KDMN: $-120M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$26.39M
5.78% YoY

As of Sep 30, 2021

Annual EBIT (TTM)

-$117.02M
31.03% YoY

Trailing 12 months ending Sep 30, 2021

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Kadmon Holdings (KDMN) FAQ

The latest EBIT for KDMN is $-120M as of September 2021. That compares with $-89M in the prior-year period — down 31.0% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Kadmon Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, KDMN's EBIT moved from $-89M to $-120M — a 31.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Kadmon Holdings's operating scale or balance-sheet position.

Against Healthcare companies, KDMN currently prints $-120M for EBIT, while the sector average sits near $22B. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Kadmon Holdings's growth, margins, and balance sheet.

A EBIT figure of $-120M for KDMN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting KDMN's EBIT ($-120M), review year-over-year change from $-89M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.